SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
SAB Biotherapeutics's price to sales ratio was 11.9× on Apr 30, 2025, against 17.7× a year earlier. Over the last 4 years it ranged from 0.6× to 23.1×, with a median of 6.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 11.9× | −11.2 |
| 2024 | Dec 31, 2024 | 23.1× | +7.6 |
| 2023 | Dec 29, 2023 | 15.5× | +14.1 |
| 2022 | Dec 30, 2022 | 1.4× | +0.5 |
| 2021 | Dec 31, 2021 | 0.8× | – |